Aurobindo Pharma receives USFDA approval for Oxymorphone Hydrochloride Tablets

27 Apr 2016 Evaluate

Aurobindo Pharma has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Oxymorphone Hydrochloride Tablets, 5 mg and 10 mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Opana (oxymorphone hydrochloride) Tablets, 5 mg and 10 mg, of Endo Pharmaceuticals, Inc.

Oxymorphone Hydrochloride Tablets is used to help relieve moderate to severe acute pain where the use of an opioid is appropriate. The approved product has an estimated market size of $55.5 million for the twelve months ending February 2016 according to IMS.

This is the 11th ANDA to be approved out of Aurolife formulation facility in New Jersey, USA for manufacturing Non-Antibiotic products & Controlled substances. Aurobindo now has a total of 257 ANDA approvals (220 Final approvals including 11 from Aurolife Pharma LLC and 37 tentative approvals) from USFDA.


Aurobindo Pharma Share Price

1167.20 -5.10 (-0.44%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×